Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Expert opinion : defining response to omalizumab in patients with chronic spontaneous urticaria. / Ferrer, Marta; Boccon-Gibod, Isabelle; Gonçalo, Margarida; İnalöz, Hüseyin Serhat; Knulst, André; Lapeere, Hilde; Parthasaradhi, Anchala; Stingl, Georg; Tagka, Anna; Valenzuela, Fernando; Yeung, Jensen; Thomsen, Simon Francis.

I: European Journal of Dermatology, Bind 27, Nr. 5, 2017, s. 455-463.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Ferrer, M, Boccon-Gibod, I, Gonçalo, M, İnalöz, HS, Knulst, A, Lapeere, H, Parthasaradhi, A, Stingl, G, Tagka, A, Valenzuela, F, Yeung, J & Thomsen, SF 2017, 'Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria', European Journal of Dermatology, bind 27, nr. 5, s. 455-463. https://doi.org/10.1684/ejd.2017.3085

APA

Ferrer, M., Boccon-Gibod, I., Gonçalo, M., İnalöz, H. S., Knulst, A., Lapeere, H., ... Thomsen, S. F. (2017). Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria. European Journal of Dermatology, 27(5), 455-463. https://doi.org/10.1684/ejd.2017.3085

Vancouver

Ferrer M, Boccon-Gibod I, Gonçalo M, İnalöz HS, Knulst A, Lapeere H o.a. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria. European Journal of Dermatology. 2017;27(5):455-463. https://doi.org/10.1684/ejd.2017.3085

Author

Ferrer, Marta ; Boccon-Gibod, Isabelle ; Gonçalo, Margarida ; İnalöz, Hüseyin Serhat ; Knulst, André ; Lapeere, Hilde ; Parthasaradhi, Anchala ; Stingl, Georg ; Tagka, Anna ; Valenzuela, Fernando ; Yeung, Jensen ; Thomsen, Simon Francis. / Expert opinion : defining response to omalizumab in patients with chronic spontaneous urticaria. I: European Journal of Dermatology. 2017 ; Bind 27, Nr. 5. s. 455-463.

Bibtex

@article{6f862b7597754563bdd158cc4ea22466,
title = "Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria",
abstract = "Omalizumab (a recombinant, humanized anti-immunoglobulin-E antibody) has been shown in three pivotal Phase III trials (ASTERIA I, II and GLACIAL) and real-world studies to be effective and well-tolerated for the treatment of chronic spontaneous urticaria (CSU), and is the only licensed third-line treatment for CSU. However, the definition of response to omalizumab treatment often differs between clinical trials, real-world studies, and daily practice of individual physicians globally. As such, a consensus definition of {"}complete{"}, {"}partial{"} and {"}non-response{"} to omalizumab is required in order to harmonize treatment management and compare data. Here, it is proposed that a disease measurement tool, for example, the 7-Day Urticaria Activity Score (UAS7) or Urticaria Control Test (UCT) is required for defining response. The addition of quality of life measurements is helpful to gain insight into a patient's disease burden and its changes during treatment. A potential omalizumab treatment approach based on speed and pattern of response at 1-3 and 3-6 months is suggested. In cases where there is no response during the first 1-3 months, physicians should consider reassessing the original CSU diagnosis. Moreover, in patients showing partial response at 12 weeks, treatment with omalizumab should be continued in order to maximize the possibility of achieving symptom control. If patients have a UAS7>6 and/or UCT<12, then continued treatment is advised, dependent on physician judgement and patient expectations. In treatment responders, omalizumab treatment can be resumed at a later stage after discontinuation with the same degree of symptom control.",
keywords = "Journal Article",
author = "Marta Ferrer and Isabelle Boccon-Gibod and Margarida Gon{\cc}alo and İnal{\"o}z, {H{\"u}seyin Serhat} and Andr{\'e} Knulst and Hilde Lapeere and Anchala Parthasaradhi and Georg Stingl and Anna Tagka and Fernando Valenzuela and Jensen Yeung and Thomsen, {Simon Francis}",
year = "2017",
doi = "10.1684/ejd.2017.3085",
language = "English",
volume = "27",
pages = "455--463",
journal = "European Journal of Dermatology",
issn = "1167-1122",
publisher = "JohnLibbey Eurotext",
number = "5",

}

RIS

TY - JOUR

T1 - Expert opinion

T2 - defining response to omalizumab in patients with chronic spontaneous urticaria

AU - Ferrer, Marta

AU - Boccon-Gibod, Isabelle

AU - Gonçalo, Margarida

AU - İnalöz, Hüseyin Serhat

AU - Knulst, André

AU - Lapeere, Hilde

AU - Parthasaradhi, Anchala

AU - Stingl, Georg

AU - Tagka, Anna

AU - Valenzuela, Fernando

AU - Yeung, Jensen

AU - Thomsen, Simon Francis

PY - 2017

Y1 - 2017

N2 - Omalizumab (a recombinant, humanized anti-immunoglobulin-E antibody) has been shown in three pivotal Phase III trials (ASTERIA I, II and GLACIAL) and real-world studies to be effective and well-tolerated for the treatment of chronic spontaneous urticaria (CSU), and is the only licensed third-line treatment for CSU. However, the definition of response to omalizumab treatment often differs between clinical trials, real-world studies, and daily practice of individual physicians globally. As such, a consensus definition of "complete", "partial" and "non-response" to omalizumab is required in order to harmonize treatment management and compare data. Here, it is proposed that a disease measurement tool, for example, the 7-Day Urticaria Activity Score (UAS7) or Urticaria Control Test (UCT) is required for defining response. The addition of quality of life measurements is helpful to gain insight into a patient's disease burden and its changes during treatment. A potential omalizumab treatment approach based on speed and pattern of response at 1-3 and 3-6 months is suggested. In cases where there is no response during the first 1-3 months, physicians should consider reassessing the original CSU diagnosis. Moreover, in patients showing partial response at 12 weeks, treatment with omalizumab should be continued in order to maximize the possibility of achieving symptom control. If patients have a UAS7>6 and/or UCT<12, then continued treatment is advised, dependent on physician judgement and patient expectations. In treatment responders, omalizumab treatment can be resumed at a later stage after discontinuation with the same degree of symptom control.

AB - Omalizumab (a recombinant, humanized anti-immunoglobulin-E antibody) has been shown in three pivotal Phase III trials (ASTERIA I, II and GLACIAL) and real-world studies to be effective and well-tolerated for the treatment of chronic spontaneous urticaria (CSU), and is the only licensed third-line treatment for CSU. However, the definition of response to omalizumab treatment often differs between clinical trials, real-world studies, and daily practice of individual physicians globally. As such, a consensus definition of "complete", "partial" and "non-response" to omalizumab is required in order to harmonize treatment management and compare data. Here, it is proposed that a disease measurement tool, for example, the 7-Day Urticaria Activity Score (UAS7) or Urticaria Control Test (UCT) is required for defining response. The addition of quality of life measurements is helpful to gain insight into a patient's disease burden and its changes during treatment. A potential omalizumab treatment approach based on speed and pattern of response at 1-3 and 3-6 months is suggested. In cases where there is no response during the first 1-3 months, physicians should consider reassessing the original CSU diagnosis. Moreover, in patients showing partial response at 12 weeks, treatment with omalizumab should be continued in order to maximize the possibility of achieving symptom control. If patients have a UAS7>6 and/or UCT<12, then continued treatment is advised, dependent on physician judgement and patient expectations. In treatment responders, omalizumab treatment can be resumed at a later stage after discontinuation with the same degree of symptom control.

KW - Journal Article

U2 - 10.1684/ejd.2017.3085

DO - 10.1684/ejd.2017.3085

M3 - Review

C2 - 29084635

VL - 27

SP - 455

EP - 463

JO - European Journal of Dermatology

JF - European Journal of Dermatology

SN - 1167-1122

IS - 5

ER -

ID: 189624757